VYGR
$3.92
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Intraday
Recent News
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?
Voyager Therapeutics, Inc. reported fourth-quarter 2025 results showing a net loss of US$27.43 million versus US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 million from US$65.00 million. Although the quarterly loss per share from continuing operations narrowed to US$0.47 basic (US$0.46 diluted), the full-year loss per share increased to US$2.04 basic and diluted, underscoring the cost of advancing its neurology-focused pipeline. We’ll now examine how...
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +15.08% and +57.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics: Q4 Earnings Snapshot
LEXINGTON, Mass. AP) — Voyager Therapeutics Inc. VYGR) on Monday reported a loss of $27.4 million in its fourth quarter.
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028
Voyager Therapeutics (NASDAQ:VYGR) outlined what CEO Al Sandrock described as three “pillars of value” for the year ahead during a discussion at Oppenheimer’s 36th Annual Life Science Conference, pointing to advancing two tau-directed programs, initiating two gene therapy clinical entries using its
Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -42.82% and -1.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?